Structure-based development of PDEδ inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Prenyl binding protein PDEδ facilitates the cytosolic diffusion of farnesylated proteins, including Ras.
• Proper localization and signaling of Ras proteins are crucial for cellular functions.
• Aberrant KRas signaling is implicated in various oncogenic processes, making PDEδ a potential therapeutic target.

Purpose of the Study:

• To review the structure-guided development of PDEδ inhibitors.
• To compare the potency and in vivo efficiency of different PDEδ inhibitor chemotypes.
• To assess the potential of PDEδ inhibition in suppressing oncogenic KRas signaling.

Main Methods:

• Structure-guided drug design principles were applied.
• Development and characterization of three distinct PDEδ inhibitor chemotypes.
• Evaluation of inhibitor binding affinity to the PDEδ pocket.
• Assessment of in vivo efficacy in suppressing oncogenic KRas signaling.

Main Results:

• Three distinct chemotypes of PDEδ inhibitors have been developed.
• These inhibitors exhibit varying potencies in binding to the PDEδ pocket.
• In vivo studies demonstrate the efficiency of these inhibitors in suppressing oncogenic KRas signaling by disrupting the PDEδ/KRas interaction.

Conclusions:

• PDEδ is a validated target for inhibiting oncogenic KRas signaling.
• Structure-guided development has yielded multiple chemotypes of PDEδ inhibitors.
• These inhibitors show promise for therapeutic strategies against KRas-driven cancers.